1. Occurrence of multi-carbapenemase-producing Enterobacterales in a tertiary hospital in Madrid (Spain): A new epidemiologic scenario.
- Author
-
Cabello M, Hernández-García M, Maruri-Aransolo A, Michelena M, Pérez-Viso B, Ponce-Alonso M, Cantón R, and Ruiz-Garbajosa P
- Subjects
- Humans, Spain epidemiology, Female, Male, Middle Aged, Aged, Adult, Klebsiella pneumoniae drug effects, Klebsiella pneumoniae genetics, Klebsiella pneumoniae isolation & purification, Klebsiella pneumoniae enzymology, Aged, 80 and over, Escherichia coli genetics, Escherichia coli drug effects, Escherichia coli isolation & purification, Escherichia coli enzymology, Citrobacter freundii genetics, Citrobacter freundii drug effects, Citrobacter freundii isolation & purification, Citrobacter freundii enzymology, Drug Combinations, Azabicyclo Compounds pharmacology, Drug Resistance, Multiple, Bacterial, Klebsiella oxytoca drug effects, Klebsiella oxytoca genetics, Klebsiella oxytoca isolation & purification, Klebsiella oxytoca enzymology, Ceftazidime pharmacology, Enterobacter genetics, Enterobacter drug effects, Enterobacter isolation & purification, Enterobacter enzymology, Prospective Studies, Carbapenems pharmacology, Enterobacteriaceae drug effects, Enterobacteriaceae genetics, Enterobacteriaceae enzymology, Enterobacteriaceae isolation & purification, beta-Lactamases genetics, beta-Lactamases metabolism, Bacterial Proteins genetics, Bacterial Proteins metabolism, Enterobacteriaceae Infections microbiology, Enterobacteriaceae Infections epidemiology, Tertiary Care Centers statistics & numerical data, Microbial Sensitivity Tests, Anti-Bacterial Agents pharmacology, Carbapenem-Resistant Enterobacteriaceae genetics, Carbapenem-Resistant Enterobacteriaceae drug effects, Carbapenem-Resistant Enterobacteriaceae isolation & purification
- Abstract
Introduction: Multi-carbapenemase-producing Enterobacterales (M-CPE) are increasingly described. We characterized the M-CPE isolates prospectively recovered in our hospital (Madrid, Spain) over two years (2021-2022)., Methods: We collected 796 carbapenem resistant Enterobacterales (CRE) from clinical and surveillance samples. Carbapenemase production was confirmed with phenotypic (immunochromatographic, disk diffusion) and molecular (PCR, WGS) techniques. Antimicrobial susceptibility was evaluated by a standard broth microdilution method. Clinical and demographic data were collected., Results: Overall, 23 M-CPE (10 Klebsiella pneumoniae, 6 Citrobacter freundii complex, 3 Escherichia coli, 2 Klebsiella oxytoca, and 2 Enterobacter hormaechei) isolates were recovered from 17 patients (3% with CPE, 0.26-0.28 cases per 1000 admissions). OXA-48 + KPC-3 (7/23) and KPC-3 + VIM-1 (5/23) were the most frequent carbapenemase combinations. All patients had prior antibiotics exposure, including carbapenems (8/17). High resistance rates to ceftazidime/avibactam (14/23), imipenem/relebactam (16/23) and meropenem/vaborbactam (7/23) were found. Ceftazidime/avibactam + aztreonam combination was synergistic in all metallo-β-lactamase producers. Clonal and non-clonal related isolates were found, particularly in K. pneumoniae (5 ST29, 3 ST147, 3 ST307) and C. freundii (3 ST8, 2 ST125, 1 ST563). NDM-1 + OXA-48 was introduced with the ST147-K. pneumoniae high-risk clone linked to the transfer of a Ukrainian patient. We identified four possible nosocomial clonal transmission events between patients of the same clone with the same combination of carbapenemases (KPC-3 + VIM-1-ST29-K. pneumoniae, NDM-1 + OXA-48-ST147-K. pneumoniae and KPC-2 + VIM-1-ST145-K. oxytoca). Carbapenemase-encoding genes were located on different plasmids, except for VIM-1 + KPC-2-ST145-K. oxytoca. Cross-species transmission and a possible acquisition overtime was found, particularly between K. pneumoniae and E. coli producing OXA-48 + KPC-3., Conclusion: M-CPE is an emerging threat in our hospital. Co-production of different carbapenemases, including metallo-β-lactamases, limits therapeutic options and depicts the need to reinforce infection control measures., Competing Interests: Declaration of competing interest None., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF